Go to the profile of Efung Capital

Efung Capital


About Efung Capital

Shenzhen Efung Capital, one of the earliest VC/PE companies in China, focuses on the investment of biopharmaceutical and medical device companies. Efung has invested about 20 new drug and medical device companies in China and internationally. Of which, Chipscreen (Shenzhen) marketed an anti-cancer new drug, Chidamide, in 2015; Frontier Biotech(Nanjing)will market Albuvirtide within months, which could become one of the world's first long-acting anti-HIV new drug ever approved; Ascentage Pharma (Jiangsu) and Gmax Biopharm (Hangzhou) will be IPO in NASDAQ in 2018. Since 2015, Efung initiated two U.S. Dollar Fundings and already invested 5 Pharmaceutical companies, such as Aridis, Reservlogix, Centrexion, et.al. We collaborate with many individual and institution investors, public listed pharmaceutical/medical device companies, investing banks and governmental agents from China, and internationally.

Therapeutic Areas

Cardiovascular Infectious Metabolic Oncology


Antimicrobial Diagnostics Drug delivery Regenerative medicine

Company Type


State of Ownership


Sponsorship Group


Influencer Of


Editions participated in:

June 2018